Adaptive Biotechnologies (ADPT) Non-Current Assets (2018 - 2026)

Adaptive Biotechnologies has reported Non-Current Assets for 9 years, with the latest figure at $214.1 million in Q1 2026.

• Quarterly Non-Current Assets fell 15.81% year-over-year to $214.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $870.6 million (down 12.36% YoY) and the FY2025 annual result came in at $212.6 million, down 16.85% from the prior year.
• Non-Current Assets improved to $214.1 million in Q1 2026 per ADPT's latest filing, from $212.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $439.1 million in Q1 2022 and troughed at $209.2 million in Q3 2025.
• A 5-year average of $273.1 million and a median of $254.4 million in 2025 frame the typical range for Non-Current Assets.
• The widest YoY moves for Non-Current Assets: up 42.96% in 2022, down 43.44% in 2022.
• Over 5 years, Non-Current Assets stood at $294.5 million in 2022, then declined by 14.78% to $250.9 million in 2023, then advanced by 1.86% to $255.6 million in 2024, then declined by 16.85% to $212.6 million in 2025, then rose by 0.75% to $214.1 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $214.1 million, $212.6 million, and $209.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.